Drug Trial Radar · NCT05239468
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Mar 21, 2022
Primary completion
Sep 1, 2025
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
Conditions
- Primary Biliary Cholangitis
Interventions
Bezafibrate 100 mgDrug
One tablet of bezafibrate 100 mg IR once daily
Bezafibrate 200 mgDrug
Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
Obeticholic Acid 5 mgDrug
One tablet of obeticholic acid 5 mg tablet once daily.
Obeticholic Acid placeboDrug
One tablet of obeticholic acid placebo tablet once daily
Bezafibrate PlaceboDrug
One tablet of bezafibrate placebo tablet once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alkaline Phosphatase (ALP)Time frame: Baseline to Week 12
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado
Coronado, California
Facey Medical Group
Mission Hills, California
Schiff Center for Liver Diseases / University of Miami
Miami, Florida
Tampa General Medical Group
Tampa, Florida
Piedmont Atlanta Hospital
Atlanta, Georgia
Loyola University Medical Center
Maywood, Illinois
Ochsner Medical Center
New Orleans, Louisiana
Beth Israel Deaconess Medical Center Harvard Liver Research Center
Boston, Massachusetts
NYU Langone Medical Center
New York, New York
Wake Endoscopy Center
Raleigh, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Gastro One
Cordova, Tennessee
Gastrointestinal Associates of Northeast Tennessee
Johnson City, Tennessee
Methodist Clinical Research Institute (CRI)
Dallas, Texas
Houston Methodist Cancer Center
Houston, Texas
American Research Corporation at the Texas Liver Institute
San Antonio, Texas
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Argentina
Hospital Provincial del Centenario
Rosario, Argentina
Hospital Italiano La Plata
La Plata, Buenos Aires, Argentina
DIM Clinical Privada
Ramos Mejía, Buenos Aires, Argentina
The Northern Alberta Clinical Trials and Research Centre
Edmonton, Alberta, Canada
Pacific Gastroenterology Associates
Vancouver, British Columbia, Canada
University of Montreal
Montreal, Quebec, Canada
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.